NCT00854854Unknown1 期
Evaluating the Safety and Efficacy of Combination Therapy With FOLFOX-4 and TKcell Therapy Versus FOLFOX-4 Alone in Patients With Recurrent, Unresectable and Advanced Gastric Cancer
适应症
试验速览
- 阶段
- 1 期
- 发起方
- Binex
- 入组人数
- 94
- 试验地点
- 1
- 主要终点
- Determine response rate
研究概览
简要总结
The purpose of this study is to determine efficacy of NKCell combined FOLFOX-4 chemotherapy in gastric cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent.
- •Diagnosis of histologically confirmed adenocarcinoma of the gastric
- •ECOG performance status of 0 - 2
- •At least one definite measurable lesion(s): ≥ 1 cm on spiral CT scan or ≥2cm in physical examination
- •Adequate liver, renal, bone marrow functions as evidence by the following; Absolute neutrophil count > 1.5 x 109/L; platelets > 7.5 x 109/L; Bilirubin less than 2 mg/dL ASAT and/or ALAT < 5 UNL; serum creatinine ≤ 2 ULN
- •Minimum life expectancy of 12 weeks
- •Effective contraception for both male and female subjects if the risk of conception exists
排除标准
- •Brain metastasis and/or leptomeningeal disease (known or suspected)
- •Previous chemotherapy for gastric cancer except adjuvant treatment with progression of disease documented > 6 months after end of adjuvant treatment.
- •Previous oxaliplatin-based chemotherapy
- •Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to randomization and chemotherapy
- •HIV antibody (+), Chronic hepatitis
- •Uncontrolled infection
- •Concurrent or previous chronic systemic immune therapy, targeted therapy, hormonal therapy not indicated in the study protocol except for contraception
- •Clinically relevant coronary artery disease, history of myocardial infarction, high risk of uncontrolled arrhythmia
- •Known hypersensitivity reaction to any of the components of the treatment.
- •Pregnancy (absence to be confirmed by ß-hCG test) or lactation period
- •Participation in another clinical study within the 30 days before randomization
- •Significant disease which, in the investigator's opinion, would exclude the subject from the study
结局指标
主要结局
Determine response rate
时间窗: within study period
次要结局
- Determine safety of combination,time to treatment failure, overall survival time(within study period)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Efficacy Study of TKcell in Advanced Colorectal CancerAdvanced Colorectal CancerNCT00854971Binex86
已完成
1 期
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)LeukemiaMyelodysplastic SyndromeNCT00402558M.D. Anderson Cancer Center15
Unknown
不适用
Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT PatientsCarcinoma, HepatocellularNCT02813096Guangxi Medical University500
已完成
2 期
A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRCColorectal NeoplasmsNCT02246049EPS Corporation69
尚未招募
早期 1 期
Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological MalignanciesHematological MalignanciesNCT04662788Zhejiang University36